دورية أكاديمية

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.

التفاصيل البيبلوغرافية
العنوان: Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.
المؤلفون: Wheeler, S. E., Suzuki, S., Thomas, S. M., Sen, M., Leeman-Neill, R. J., Chiosea, S. I., Kuan, C-T., Bigner, D. D., Gooding, W. E., Lai, S. Y., Grandis, J. R.
المصدر: Oncogene; 9/16/2010, Vol. 29 Issue 37, p5135-5145, 11p, 5 Black and White Photographs, 1 Graph
مصطلحات موضوعية: EPIDERMAL growth factor, SQUAMOUS cell carcinoma, TUMOR growth, MONOCLONAL antibodies, CETUXIMAB, METASTASIS, CELL migration, CANCER cell proliferation, THERAPEUTICS
مستخلص: Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth. EGFR variant III (EGFRvIII) is the most commonly altered form of EGFR and contains a truncated ligand-binding domain. We previously reported that EGFRvIII is expressed in up to 40% of HNSCC tumors where it is associated with increased proliferation, tumor growth and chemoresistance to antitumor drugs including the EGFR-targeting monoclonal antibody cetuximab. Cetuximab was FDA-approved in 2006 for HNSCC but has not been shown to prevent invasion or metastasis. This study was undertaken to evaluate the mechanisms of EGFRvIII-mediated cell motility and invasion in HNSCC. We found that EGFRvIII induced HNSCC cell migration and invasion in conjunction with increased signal transducer and activator of transcription 3 (STAT3) activation, which was not abrogated by cetuximab treatment. Further investigation showed that EGF-induced expression of the STAT3 target gene HIF1-α, was abolished by cetuximab in HNSCC cells expressing wild-type EGFR under hypoxic conditions, but not in EGFRvIII-expressing HNSCC cells. These results suggest that EGFRvIII mediates HNSCC cell migration and invasion by increased STAT3 activation and induction of HIF1-α, which contribute to cetuximab resistance in EGFRvIII-expressing HNSCC tumors. [ABSTRACT FROM AUTHOR]
Copyright of Oncogene is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:09509232
DOI:10.1038/onc.2009.279